We are excited to introduce "FILLRIE," our monophasic filler currently undergoing CE MDR certification, with an anticipated acquisition scheduled for the fourth quarter of its 25th year. Furthermore, we expect KFDA approval by April of its 24th year.

"FILLRIE" offers a range of three types: soft, medium, and hard, each meticulously crafted to optimize particle size for different skin layers. With a generous 1.0ml capacity per syringe, containing 24mg of hyaluronic acid and 3% lidocaine, "FILLRIE" ensures versatility and ease of application.

Our product is designed with impeccable biocompatibility, ensuring safe and reliable procedures. With a homogenous hyaluronic acid crosslinked structure, "FILLRIE" provides consistent injection performance and superior formulation. Backed by our advanced technology for manufacturing high purity hyaluronic acid fillers, it maintains the best crosslinking ratio for optimal results, minimizing potential side effects.